New Hampshire ADAP limits Fuzeon access

The New Hampshire AIDS Drug Assistance Program maintains a policy that allows only two low-income HIV patients in the program at any one time to have access to Fuzeon, an expensive HIV entry inhibitor, NHPR News reports. The drug is offered on a first-come, first-served basis to two ADAP enrollees. All other ADAP patients seeking the drug are placed on a waiting list. Fuzeon costs about $20,000 per person per year, but is offered to ADAPs by drugmakers Roche and Trimeris at a reduced price. However, even that price is too high for many public drug programs, like New Hampshire's, to widely provide the medication. Fuzeon is the only HIV entry inhibitor on the market. The injectable drug works by preventing HIV from latching onto and infecting immune system cells